This CME program will highlight the McDonal Criteria 2024 for the management of patients with multiple sclerosis. The expert faculty, Dr. Joseph Berger, will review the new updates of the McDonald Criteria 2024 to make an early and accurate diagnosis of multiple sclerosis. Dr. Berger will also discuss biomarkers and advanced imaging options to evaluate patients with MS. Upon completion of this program, learners will gain insight into how to better treat their patients with multiple sclerosis.
Neurologists and other HCPs who manage patients with multiple sclerosis.
Discuss the new updates of the McDonald Criteria 2024 to make an early and accurate diagnosis of multiple sclerosis.
Review biomarkers and advanced imaging options to evaluate patients with MS.
Updates to the McDonald Criteria 2024 for Early and Accurate Diagnosis of Multiple Sclerosis
Review of Biomarkers and Advanced Imaging Options to Evaluate Patients with MS
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Joseph Berger, MD | Consultant/Advisor: Bristol-Myers Squibb Company; Celgene Corporation; Cycle Pharma; Dice Therapeutics; Excision BioTherapeutics, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Merck & Co., Inc.; Morphic Therapeutics; Novartis AG; Pfizer Inc.; Population Bio, Inc; Sandoz Group AG; Seagen; Takeda Pharmaceutical Company Limited; TG Therapeutics
Speaker’s Bureau: TG Therapeutics |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from EMD Serono.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and EMD Serono do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
